Syntaxin
OXFORD, England, March 2, 2011 - Syntaxin, a biotechnology company developing novel
biopharmaceuticals to control cell secretion, today announces its partner
Allergan, Inc has initiated two Phase II trials to evaluate the safety and
efficacy of its re-targeted endopeptidase drug candidate AGN-214868.
OXFORD, England, January 6, 2011 - Syntaxin, a biotechnology company developing novel biopharmaceuticals to
control cell secretion, today announced Dr Russell G.
OXFORD, England, November 11, 2010 - Syntaxin, a biotechnology company developing novel
biopharmaceuticals to control cell secretion, announces it has successfully
raised GBP18 million in new funding.
